SCHEMBL30748879

SCHEMBL30748879

O=C1Cc2cnc(Cl)nc2N1c1ccc(Oc2ccccc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.44
MAPT P10636 2/20 0.44
USP2 O75604 1/20 0.44
ALOX15 P16050 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
MGLL Q99685 1/20 0.43
PLCG1 P19174 1/20 0.40
LMNA P02545 2/20 0.40
GAA P10253 3/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
PIN1 Q13526 3/20 0.39
HPGD P15428 2/20 0.38
KDM4E B2RXH2 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
CTSG P08311 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30749142 0.89 ALDH1A1 (0.45) ALDH1A1MAPTUSP2ALOX15TDP1
SCHEMBL30748809 0.75 CCNE1 (0.45) ALDH1A1MAPTUSP2ALOX15TDP1
SCHEMBL30749141 0.73 AR (0.34) MAPTMEN1KMT2AKDM4E
SCHEMBL30748875 0.73 LIPE (0.36) ALDH1A1
SCHEMBL30748892 0.73 MGLL (0.41) ALDH1A1MAPTUSP2ALOX15TDP1
SCHEMBL30748788 0.72 MGLL (0.40) ALDH1A1MAPTUSP2ALOX15TDP1
SCHEMBL30748992 0.72 KMT2A (0.43) ALDH1A1MAPTUSP2ALOX15TDP1
SCHEMBL30748844 0.71 AR (0.35)
SCHEMBL4686776 0.71 FGFR4 (0.47) MAPTTDP1KDM4ECTSGCMA1
SCHEMBL30749030 0.68 PIN1 (0.40) MAPTTDP1MGLLPLCG1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2025-10-02 US disclosed
EP-4565588-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF Suzhou Keen Therapeutics Co., Ltd. (CN) 2025-06-11 EP disclosed
WO-2023241620-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2023-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF VHL, BRCA1, TERT ALDH1A1 256/4885MAPT 3029/4885USP2 4313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.